Mechanisms of Peitu Yimu acupuncture in repairing intestinal mucosal barrier by regulating CRF/CRFR1 pathway in diarrhea-predominant irritable bowel syndrome rats.

Researchers studying irritable bowel syndrome with diarrhea (IBS-D) have discovered how a specific acupuncture approach called "Peitu Yimu" (strengthening spleen and soothing liver) may help repair the intestinal lining and reduce symptoms. The study used rats with IBS-D-like conditions and tested acupuncture at three specific points: Tianshu (ST25), Zusanli (ST36), and Taichong (LR3). The treatment involved electroacupuncture for 20 minutes every other day for two weeks. The results showed significant improvements in multiple areas. Rats receiving acupuncture experienced less visceral pain and had improved stool consistency compared to untreated rats. They also showed reduced anxiety and depression-like behaviors, moving more freely in open spaces. The researchers discovered that acupuncture worked by affecting a specific biological pathway involving corticotropin-releasing factor (CRF) and its receptor. This pathway is known to influence stress responses and gut function. By calming this pathway, acupuncture helped restore the protective proteins that form tight junctions in the intestinal lining, essentially repairing the gut barrier that becomes damaged in IBS-D. The study provides scientific evidence for why acupuncture may benefit people with IBS-D, particularly those experiencing both digestive symptoms and emotional distress. The treatment appeared to address both the physical intestinal damage and the anxiety-depression components often seen together in IBS-D patients. If you're considering acupuncture for IBS-D, consult with a licensed acupuncturist experienced in digestive disorders.

This animal study (n=40 female SD rats) investigated Peitu Yimu acupuncture's mechanism in IBS-D through the CRF/CRFR1 pathway. Rats received acupuncture at ST25 and electroacupuncture (2/15 Hz) at ST36 and LR3 for 20 minutes, alternating sides every other day for 14 days. Results demonstrated significant improvements (P<0.01) in visceral pain threshold, Bristol stool scores, and anxiety-depression behaviors compared to model group. Mechanistically, treatment significantly decreased serum CRF and CRFR1 levels and their colonic expression while upregulating tight junction proteins (ZO-1, Occludin, Claudin-1) (P<0.01). The agonist group receiving CRFR1 activator showed partial reversal of effects, confirming pathway specificity. Clinical implications suggest this point combination may address both gut barrier dysfunction and psychological comorbidities in IBS-D through CRF/CRFR1 pathway inhibition. The 14-day protocol with alternating bilateral treatment represents a practical treatment schedule for clinical application in diarrhea-predominant IBS patients with anxiety-depression presentations.